Aptose Biosciences: Q4 Earnings Insights
Aptose Biosciences (NASDAQ:APTO) reported its Q4 earnings results on Tuesday, March 22, 2022 at 04:01 PM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Merck’s Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Preview: Aptose Biosciences
Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement.
Analysts estimate that Aptose Biosciences will report an earnings per share (EPS) of $-0.17.
Earnings Preview For Aptose Biosciences
Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement.
Analysts estimate that Aptose Biosciences will report an earnings per share (EPS) of $-0.17.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Aptose Biosciences Announces Its Decision To Discontinue Further Clinical Development Of APTO-253
Aptose Biosciences Inc. ("Aptose") (NASDAQ:APTO, TSX:APS) today announced its decision to discontinue further clinical development of APTO-253. The decision follows prioritization of the company's other
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
58 Biggest Movers From Yesterday
Gainers
Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price target from Jefferies.